MENU
AKBA
AS OF
Feb 4, 02:46 PM (EDT)
Price
$1.37
Change
-$0.04 (-2.84%)
Capitalization
374.17M
36 days until earnings call
Intraday BUY SELL Signals
+Compare
AKBA
Stock ticker: NASDAQ
AS OF
Feb 4, 02:46 PM (EDT)
Price
$1.37
Change
-$0.04 (-2.84%)
Capitalization
374.17M

AKBA Akebia Therapeutics Forecast, Technical & Fundamental Analysis

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more

Industry: #Biotechnology
AKBA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for AKBA with price predictions
Feb 03, 2026

AKBA's RSI Indicator ascends from oversold territory

The RSI Oscillator for AKBA moved out of oversold territory on January 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In of the 27 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 27, 2026. You may want to consider a long position or call options on AKBA as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AKBA just turned positive on January 22, 2026. Looking at past instances where AKBA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where AKBA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AKBA entered a downward trend on January 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.993) is normal, around the industry mean (29.792). P/E Ratio (0.000) is within average values for comparable stocks, (74.095). AKBA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.035). AKBA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (1.577) is also within normal values, averaging (116.680).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
AKBA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

AKBA is expected to report earnings to rise ∞% to 0 cents per share on March 12

Akebia Therapeutics AKBA Stock Earnings Reports
Q4'25
Est.
$0.00
Q3'25
Beat
by $0.04
Q2'25
Beat
by $0.02
Q1'25
Beat
by $0.08
Q4'24
Missed
by $0.03
The last earnings report on November 10 showed earnings per share of 0 cents, beating the estimate of -3 cents. With 574.15K shares outstanding, the current market capitalization sits at 374.17M.
A.I. Advisor
published General Information

General Information

a developer of drugs for the treatment of anemia and vascular diseases

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Biotechnology
Address
245 First Street
Phone
+1 617 871-2098
Employees
167
Web
https://www.akebia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TMAPX56.90-0.06
-0.11%
Touchstone Mid Cap A
GSPUX42.20-0.34
-0.80%
Goldman Sachs Large Cap Equity R6
QIMGF0.28N/A
-1.21%
QUIMBAYA GOLD INC
BRWTX26.98-0.50
-1.82%
MFS Blended Research Growth Eq R3
RECAF0.57-0.01
-2.06%
Reconnaissance Energy Africa Ltd.

AKBA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+2.17%
XERS - AKBA
39%
Loosely correlated
-0.27%
IPSC - AKBA
38%
Loosely correlated
N/A
SYRE - AKBA
37%
Loosely correlated
+1.65%
FENC - AKBA
36%
Loosely correlated
+1.02%
RXRX - AKBA
36%
Loosely correlated
-1.91%
More

Groups containing AKBA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+2.17%
Pharmaceuticals
category (380 stocks)
24%
Poorly correlated
-0.30%
Pharmaceuticals: Generic
category (214 stocks)
13%
Poorly correlated
-0.59%